Objective To evaluate the efficacy and safety of neoadjuvant chemotherapies combined with surgery in the treatment of advanced gastric cancer.
Methods A total of 74 patients with advanced gastric cancer were randomly divided into two groups, with 37 cases in each group. The control group received preoperative chemotherapy by capecitabine and oxaliplatin (XELOX), while the observation group received S-1 and oxaliplatin (SOX) as neoadjuvant chemotherapy. One week after chemotherapy, patients received surgical treatment according to their conditions. The efficacy and safety of different methods were compared.
Results After treatment, the total remission rate of the observation group was significantly higher, and tumor markers such as carbohydrate antigen 724 (CA724), carbohydrate antigen 242 (CA242), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) levels were significantly lower than those in the control group(P < 0.05). The 12-month survival rate was significantly higher, and the incidence rates of adverse reactions of hand-foot skin reaction and liver function injury were significantly lower than those of the control group(P < 0.05).
Conclusion SOX neoadjuvant chemotherapy combined with surgery for advanced gastric cancer can improve the survival rate of patients, and has lower incidence rate of adverse reactions than XELOX therapy.
DownLoad: